Medivir AB (publ) (LON:0GP7)

Market Cap	17.15M
Revenue (ttm)	305.80K
Net Income (ttm)	-7.52M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,600
Average Volume	6,879
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1.254 - 3.030
Beta	0.33
RSI	32.94
Earnings Date	Aug 21, 2025

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GP7

Financial Performance

In 2024, Medivir AB's revenue was 3.48 million, a decrease of -54.36% compared to the previous year's 7.63 million. Losses were -123.32 million, 38.1% more than in 2023.

Financial numbers in SEK